Ming-Yang Chang ,M.D.,Ph.D.
Institution: Chang Gung Memorial Hospital, Chang Gung University College of Medicine 
Position: Attending Physician
Department: Division of Nephrology
Address: 5 Fu-Shin Street, Kwei-Shan, Taoyuan 333, Taiwan 
Tel:
+886-3-328-1200 ext.8181 Fax: 886-3-3282173 
E-mail:
mingyc@adm.cgmh.org.tw
Focus of Interest :- Urology & Nephrology
Fulltime Employment :
Attending Physician of Nephrology, Chang Gung Memorial Hospital-Linkou, Taoyuan, Taiwan
Education:
M.D., Taipei Medical University, Taiwan
Ph.D., University of Sheffield, United Kingdom
Honor and Awards:
Annual Research Award, Taiwan Society of Nephrology, 2012
Selected Publications:
- Chang MY*, Chen HM, Jenq CC, Lee SY, Chen YM, Tian YC, Chen YC, Hung CC, Fang JT, Yang CW, Wu-Chou YH*. Novel PKD1 and PKD2 mutations in Taiwanese patients with autosomal dominant polycystic kidney disease. J Hum Genet. 2013 Nov;58(11):720-7
- Chang MY, Ong AC*. New treatments for autosomal dominant polycystic kidney disease. Br J Clin Pharmacol. 2013 Oct;76(4):524-35.
- Chang MY, Lu JK, Tian YC, Chen YC, Hung CC, Huang YH, Chen YH, Wu MS, Yang CW, Cheng YC*. Inhibition of the P2X7 Receptor Reduces Cystogenesis in PKD. J Am Soc Nephrol. 2011; 22(9):1696-706.
- Chang MY, Parker E, Nahas ME, Haylor JL, Ong AC*. Endothelin B receptor blockade accelerates disease progression in a murine model of autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2007; 18(2):560-9.
- Chang MY, Parker E, Ibrahim S, Shortland JR, Nahas ME, Haylor JL, Ong AC*. Haploinsufficiency of Pkd2 is associated with increased tubular cell proliferation and interstitial fibrosis in two murine Pkd2 models. Nephrol Dial Transplant. 2006; 21(8):2078-84.
Full Publication List
Board Certification / Professional Affiliations:1) Board of Medical Doctor, Taiwan, 1993
2) Board of Internal Medicine, Taiwan, 1998
3) Board of Nephrology, Taiwan, 2000